In the published article, there was an error in Table 1 as published. While it stated that 3 (33%) patients received the “Chiromas” vaccine, the correct information is that 3 (33%) patients in the belatacept group received the “Vaxigrip” vaccine. The corrected Table 1 and its caption appear below.
Table 1.
Main characteristics of the study population.
| Belatacept (n=9) |
Tacrolimus (n=14) |
p value | |
|---|---|---|---|
| Time after transplantation (years) | 9.67 ± 4.19 | 3.5 ± 4.27 | 0.003 |
| Recipient age (years) | 60.8 ± 10.3 | 54.9 ± 12.3 | 0.25 |
| Recipient gender (Male) (n, %) | 8 (89%) | 9 (64%) | 0.34 |
| Donor age (years) | 60.2 ± 17.5 | 54.8 ± 13.4 | 0.51 |
| Transplant type | 0.82 | ||
| Living (n, %) | 1 (11%) | 1 (7%) | |
| DBD/DCD (n, %) | 6 (67%)/2 (22%) | 11 (79%)/2 (14%) | |
| Transplant number (1st) (n, %) | 7 (78%) | 10 (83%) | 0.48 |
| Time on dialysis (months) | 17.8 ± 18.3 | 34.3 ± 25 | 0.18 |
| Cause of ESRD (n, %) | 0.47 | ||
| Glomerular diseases | 4 (44%) | 5 (36%) | |
| Diabetic nephropathy | 0 | 1 (7%) | |
| Polycystic kidney disease | 1 (11%) | 3 (21%) | |
| Vascular/Hypertension | 1 (11%) | 2 (14%) | |
| Others | 3 (33%) | 1 (7%) | |
| Unknown | 0 | 2 (14%) | |
| Relevant comorbidities (n, %) | |||
| Diabetes | 0 | 2 (15%) | 0.49 |
| Hypertension | 6 (67%) | 11 (85%) | 0.61 |
| Heart failure | 1 (11%) | 2 (15%) | 1 |
| Previous splenectomy | 0 | 0 | |
| Induction treatment (n, %) | 0.39 | ||
| None | 1 (14%) | 0 | |
| Basiliximab | 7 (78%) | 11 (79%) | |
| rATG | 1 (14%) | 3 (21%) | |
| MMF dose (mg/d) | 826 ± 332 | 881 ± 227 | 0.66 |
| Prior anti-flu vaccination (n, %) | 7 (78%) | 12 (86%) | 1 |
| Type of vaccination (Vaxigrip) | 3 (33%) | 0 | 0.047 |
| cPRA at time of vaccination (%) | 10.2 ± 31 | 10.9 ± 22 | 0.95 |
| DSA at time of vaccination (n, %) | 0 | 2 (14%) | 0.17 |
| De novo DSA after vaccination (n, %) | 0 | 0 | 1 |
| Acute rejection prior to vaccination (n, %) | 1 (12.5%) | 2 (13%) | 1 |
| Acute rejection after vaccination (n, %) | 0 | 0 | 1 |
| eGFR at time of vaccination (mL/min/1.73m2) | 54.9 ± 22 | 63.9 ± 15 | 0.34 |
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.